Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)

Fig. 1

Study design. AGS = Aicardi-Goutières syndrome; NNS/CANDLE = Nakajo-Nishimura syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature; SAVI = STING-associated vasculopathy with onset during infancy; STING = stimulator of interferon genes; V = visit; wk = week. aPatient can skip Visit 5 and proceed to Visit 6 if biologic agents are not administered during pre-treatment period or an appropriate washout duration of biologic agents defined in Exclusion Criterion #28 has already passed at Visit 5. bVisit 801 should occur approximately 28 days after the last dose of study drug. Patients who will transition from this study to commercial baricitinib are not required to complete Visit 801

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096